Effect of BRCA2 mutation on familial breast cancer survival: A systematic review and meta-analysis

Abstract

Reports of BRCA2 genetic mutations on the prognosis of familial breast cancer (BC) patients have been contradictory. True difference in survival, if it exists, would have important implications for genetic counseling and in treatment of hereditary BC. The purpose of this study was to compare overall survival rate (OSR) among BRCA2 mutation carriers, non-carriers and sporadic BC patients. We searched the PUBMED and EMBASE databases and retrieved 4529 articles using keywords that included breast cancer, BRCA, prognosis and survival. Nine articles were selected for systematic review and among them 6 were included in our meta-analysis. We used the fixed and random effect models to calculate the summary odds ratio (OR) and corresponding 95% confidence interval (CI). BRCA2 mutation carriers had significantly higher long-term OSR than non-carriers (OR=0.69 [95% CI=0.5–0.95]), while both short-term and long-term OSR of BRCA2 mutation carriers did not differ from those of patients with sporadic disease (OR=1.11 [95% CI=0.74–1.65]; 0.85 [95% CI=0.38–1.94], respectively). For BC-specific survival rate (BCSSR), BRCA2 mutation carriers had a similar BCSSR to the non-carriers (OR=0.61 [95% CI=0.28–1.34]). There was no significant difference in disease-free survival (DFS) between BRCA2 mutation carriers and patients with sporadic disease. Our results suggest that BRCA2 mutation increases long-term OSR in hereditary BC, which reminds us a new prospect of management of the disease.

Keywords

BRCA2 gene mutation / overall survival rate / familiar breast cancer

References

[1] WoosterR, NeuhausenSL, MangionJ, et al. . Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science, 1994, 265(5181): 2088-2090 PMID: 8091231

[2] TavtigianSV, SimardJ, RommensJ, et al. . The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet, 1996, 12(3): 333-337 PMID: 8589730

[3] WoosterR, BignellG, LancasterJ, et al. . Identification of the breast cancer susceptibility gene BRCA2. Nature, 1995, 378(6559): 789-792 PMID: 8524414

[4] StrattonMR, FordD, NeuhasenS, et al. . Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet, 1994, 7(1): 103-107 PMID: 8075631

[5] LakhaniSR, JacquemierJ, SloaneJP, et al. . Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst, 1998, 90(15): 1138-1145 PMID: 9701363

[6] PhillipsKA. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol, 2000, 18: 107S-112S PMID: 11060337

[7] AgnarssonBA, JonassonJG, BjornsdottirIB, et al. . Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat, 1998, 47(2): 121-127 PMID: 9497100

[8] VerhoogLC, BernsEM, BrekelmansCT, et al. . Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol, 2000, 18(21): 119S-124S PMID: 11060339

[9] ArmakolasA, LadopoulouA, KonstantopoulouI, et al. . BRCA2 gene mutations in Greek patients with familial breast cancer. Hum Mutat, 2002, 19(1): 81-82 PMID: 11754111

[10] PhillipsKA, AndrulisIL, GoodwinPJ. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different. J Clin Oncol, 1999, 17(11): 3653-3663 PMID: 10550164

[11] GaffneyDK, BrohetRM, LewisCM, et al. . Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol, 1998, 47(2): 129-136 PMID: 9683359

[12] LeeJS, WacholderS, StruewingJP, et al. . Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst, 1999, 91(3): 259-263 PMID: 10037104

[13] VerhoogLC, BrekelmansCT, SeynaeveC, et al. . Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol, 1999, 17(11): 3396-3402 PMID: 10550133

[14] LomanN, JohannssonO, BendahlP, et al. . Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur J Cancer, 2000, 36(11): 1365-1373 PMID: 10899649

[15] BrekelmansCTM, Tilanus-LinthorstMMA, SeynaeveC, et al. . Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer, 2007, 43(5): 867-876 PMID: 17307353

[16] EerolaH, VahteristoP S L, et al. . Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A relative survival analysis from Finland. Int J Cancer, 2001, 93(3): 368-372 PMID: 11433401

[17] GoodwinPJ, PhillipsKA, WestDW, et al. . Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: An international prospective breast cancer family registry population-based cohort study. J Clin Oncol, 2012, 30(1): 19-26 PMID: 22147742

[18] LomanN, JohannssonO B P, et al. . Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur J Cancer, 2000, 36(11): 1365-1373 PMID: 10899649

[19] MollerP, EvansDG, ReisMM, et al. . Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer, 2007, 121(5): 1017-1020 PMID: 17471561

[20] SyamalaV, SyamalaVS, SreejaL, et al. . Hereditary breast/ovarian cancer: Clinicopathological characteristics and survival of BRCA2 positive and negative cases. J Exp Ther Oncol, 2008, 7(3): 227-236 PMID: 19066131

[21] AudehMW, CarmichaelJ, PensonRT, et al. . Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet, 2010, 376(9737): 245-251 PMID: 20609468

[22] KortmannU, McAlpineJN, XueH, et al. . Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res, 2011, 17(4): 783-791 PMID: 21097693

[23] MorrisSR, CareyLA. Gene expression profiling in breast cancer. Curr Opin Oncol, 2007, 19(6): 547-551 PMID: 17906450

[24] FongPC, BossDS, YapTA, et al. . Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med, 2009, 361(2): 123-134 PMID: 19553641

[25] KummarS, ChenA, JiJ, et al. . Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res, 2011, 71(17): 5626-5634 PMCID: 3166628 PMID: 21795476